On target with last year, a total of 87% of funds recorded in 2021 through biopharma collaborations with nonprofit entities by the end of October are focused on COVID-19 pandemic efforts. The pandemic accounts for 54% of the money collected through grants, which is still a sturdy amount but down from 76% in 2020.

The top 10 biopharma stock gainers and losers for the week.

Marking September as the second busiest month, 2021 is more than 6% ahead of last year in terms of reported clinical data, although the gap between the two years has narrowed significantly from 26% in April.

Biotech stocks and the overall market have taken divergent paths in the past month, not unlike what was seen throughout 2020, except this time, they are moving in opposite directions. While BioWorld’s Drug Developers Index (BDDI) appeared to be on the upswing only a month ago, it changed course in the final weeks of September.